Podcast: Jim Zukin Discusses the Reasonable Basis Review (“RBR”) for SPACs
by Kristi Marvin on 2022-07-29 at 8:33am

We spoke with Jim Zukin, the CEO & Chairman of Zukin Certification Services, and former Co-Founder of Houlihan Lokey, about his new product  – the Reasonable Basis Review, or “RBR”.

The Reasonable Basis Review is intended to help SPAC sponsors follow SEC guidance as it relates to financial projections, but also allow their target companies to have financial projections reviewed and validated by a trusted third-party.

Jim goes into why he thinks the RBR will be widely adopted by SPACs as a result of the current SEC SPAC rule proposal. But, he also believes the RBR will have a large presence in the wider M&A landscape.

Give it a listen


 

 

Recent Posts
by Nicholas Alan Clayton on 2023-09-22 at 1:48pm

Graf Acquisition Corp. IV (NYSE:GFOR) announced in an 8-K this afternoon that it has come to a forward purchase agreement (FPA) with Meteora Capital Partners involving up to 2,500,000 shares for its combination with NKGen Biotech. Meteora is to purchase up to that amount on the open market prior to close, capped at 9.9% of...

by Nicholas Alan Clayton on 2023-09-22 at 11:26am

Below is a daily summary of links to the latest SPAC news and rumors gathered across the web.  Heard on the Street: VinFast’s SPAC Backers Are Backing Out Even by the standards of electric-vehicle startups, the $40 billion market value of Vietnamese electric-vehicle startup VinFast is wild, following its combination with Black Spade last month....

by Nicholas Alan Clayton on 2023-09-22 at 10:54am

Murphy Canyon (NASDAQ:MURF) announced this morning that it has closed its combination with Conduit Pharmaceuticals and its shares and warrants are expected to begin trading on the Nasdaq under the symbols “CDT” and “CDTTW” on September 25. The company also closed a purchase of $20 million in Murphy Canyon units at close, which is to...

by Nicholas Alan Clayton on 2023-09-22 at 10:28am

Indie Semiconductor (NASDAQ:INDI), which merged with Thunder Bridge II in June 2021, announced this morning that it has launched an exchange offer to convert each outstanding warrant to 0.285 Class A shares in the company. At Indie’s last closing price of $6.22, this is $1.77 of value each, although the stock has been rising since...

by Nicholas Alan Clayton on 2023-09-22 at 10:10am

Atlantic Coastal II (NASDAQ:ACAB) has entered into a definitive agreement to combine with drug developer Abpro at a valuation of $725 million. Woburn, Massachusetts-based Abpro is advancing a series of drug candidates to potentially treat COVID, cancer and diabetic blindness. The combined company is expected to trade on the Nasdaq once the deal is completed...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved